George M. Milne Jr. - 12 Jan 2026 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
14 Jan 2026, 16:08:37 UTC
Prior SEC filing
09 Jun 2025
Next SEC filing
08 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Joshua B. Cohen, as Attorney in Fact

Key filing fact

George M. Milne Jr. filed Form 4 for Amylyx Pharmaceuticals, Inc. (AMLX) on 14 Jan 2026.

Key facts

  • This page summarizes George M. Milne Jr.'s Form 4 filing for Amylyx Pharmaceuticals, Inc. (AMLX).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 14 Jan 2026, 16:08.

Change

  • Previous filing in this sequence was filed on 09 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001179552 Primary reporting owner

MILNE GEORGE M JR

Relationship
Director
Address
C/O AMYLYX PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Signature date
14 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMLX transaction

Common Stock

Gift

Transaction value
$0
Shares
-17,780
Change %
-2.1%
Price
$0.000000
Shares after
812,881
Date
12 Jan 2026
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents a bona fide gift for no consideration.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .